Does Rhode Island Medicaid cover GLP-1s for weight loss?
Does Rhode Island Medicaid cover GLP-1s for weight loss?
Rhode Island Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". On what has to be tried or preferred first: Wegovy is the only preferred agent; Zepbound, Saxenda, oral Wegovy, Xenical, orlistat, phentermine/topiramate and Imcivree are non-preferred. Those criteria are quoted from Rhode Island Medicaid Fee for Service Preferred Drug List, read directly rather than summarized from an aggregator. Where the answer is no, the cheapest verified cash route on this site is $129 a month (compounded, not FDA approved; FDA warning letter). A Medicaid answer settles nothing about a commercial plan or a Part D plan, which set their own criteria and are asked separately.
What Rhode Island changed, and when
- 2026-10-01 — GLP-1s prescribed only for weight loss (Foundayo, Saxenda, Wegovy and Zepbound) no longer covered, under the state's fiscal 2027 budget the document that says so
What the prior authorization asks for
- Tried first
- Wegovy is the only preferred agent; Zepbound, Saxenda, oral Wegovy, Xenical, orlistat, phentermine/topiramate and Imcivree are non-preferred
- Approval runs for
- 12 months, then 12-month renewals
Under Rhode Island's fiscal 2027 budget, GLP-1s prescribed only for weight loss (Foundayo, Saxenda, Wegovy and Zepbound) are not covered from 1 October 2026, according to an EOHHS memo of 5 August 2026. Whether Xenical, phentermine-topiramate and the other non-GLP-1 drugs stay covered after that date is not yet confirmed. Prior authorization is required for the whole class, preferred or not, and an approval runs a year. The numeric threshold is in form PA04, Weight Management, which Rhode Island publishes on its pharmacy prior-authorization page. That file would not open for us on 5 September 2026 — the state's site refused every attempt, and the only copy in the Internet Archive is from March 2021 — so no BMI figure is recorded here rather than a guessed one.
Both tools fill from these criteria rather than from a template — a prior authorization for Rhode Island, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever Rhode Island decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: Rhode Island Medicaid Fee for Service Preferred Drug List , effective 2026-01-13. Read on 2026-09-05. Fee-for-service rules; a managed-care plan in Rhode Island can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.